Evidence map›Paper›PMID 29232168›Full record

ArticleSLAS discovery : advancing life sciences R & D2018

High-Throughput Screening Approach for Identifying Compounds That Inhibit Nonhomologous End Joining.

Andrea L Bredemeyer, Bruce S Edwards, Mark K Haynes, Abigail J Morales, Yinan Wang, Oleg Ursu, Anna Waller, Larry A Sklar, Barry P Sleckman

Open access · hybridAbstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Andrea L Bredemeyer1 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Bruce S Edwards2 University of New Mexico Health Sciences Center and Cancer Research and Treatment Center, Department of Pathology, Cytometry, New Mexico Molecular Libraries Screening Center, Albuquerque, NM, USA.
Mark K Haynes2 University of New Mexico Health Sciences Center and Cancer Research and Treatment Center, Department of Pathology, Cytometry, New Mexico Molecular Libraries Screening Center, Albuquerque, NM, USA.
Abigail J Morales3 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Yinan Wang3 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Oleg Ursu2 University of New Mexico Health Sciences Center and Cancer Research and Treatment Center, Department of Pathology, Cytometry, New Mexico Molecular Libraries Screening Center, Albuquerque, NM, USA.
Anna Waller2 University of New Mexico Health Sciences Center and Cancer Research and Treatment Center, Department of Pathology, Cytometry, New Mexico Molecular Libraries Screening Center, Albuquerque, NM, USA.
Larry A Sklar2 University of New Mexico Health Sciences Center and Cancer Research and Treatment Center, Department of Pathology, Cytometry, New Mexico Molecular Libraries Screening Center, Albuquerque, NM, USA.
Barry P Sleckman3 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
New Mexico Cancer Center · USCornell University · USUniversity of New Mexico · USWashington University in St. Louis · US

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Yeast Biology ConsortiumU54MH084690 · NIMH · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI TEGOS, GEORGE P · 2008 to 2013
$14.4M
New Mexico Molecular Libraries Screening Center(RMI)U54MH074425 · NIMH · UNIVERSITY OF NEW MEXICO · PI SKLAR, LARRY A. · 2005 to 2008
$10.0M
ATM FUNCTION DURING V(D)J RECOMBINATIONR01AI074953 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SLECKMAN, BARRY P · 2009 to 2023
$5.9M
NOVEL DNA DOUBLE STRAND BREAK REPAIR TARGETING THERAPEUTICS FOR CANCER TREATMENTR01CA177759 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SKLAR, LARRY A., SLECKMAN, BARRY P · 2014 to 2016
$1.4M
Advancing High Throughput Flow CytometryR01HG005066 · NHGRI · UNIVERSITY OF NEW MEXICO · PI EDWARDS, BRUCE S · 2009 to 2010
$860k
NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA177759NHGRI NIH HHS R01 HG005066NIAID NIH HHS R01 AI074953NIMH NIH HHS U54 MH074425NIMH NIH HHS U54 MH084690
6 · The paper itself

Abstract

DNA double-strand breaks (DSBs) are repaired primarily by homologous recombination (HR) or nonhomologous end joining (NHEJ). Compounds that modulate HR have shown promise as cancer therapeutics. The V(D)J recombination reaction, which assembles antigen receptor genes in lymphocytes, is initiated by the introduction of DNA DSBs at two recombining gene segments by the RAG endonuclease, followed by the NHEJ-mediated repair of these DSBs. Here, using HyperCyt automated flow cytometry, we develop a robust high-throughput screening (HTS) assay for NHEJ that utilizes engineered pre-B-cell lines where the V(D)J recombination reaction can be induced and monitored at a single-cell level. This approach, novel in processing four 384-well plates at a time in parallel, was used to screen the National Cancer Institute NeXT library to identify compounds that inhibit V(D)J recombination and NHEJ. Assessment of cell light scattering characteristics at the primary HTS stage (83,536 compounds) enabled elimination of 60% of apparent hits as false positives. Although all the active compounds that we identified had an inhibitory effect on RAG cleavage, we have established this as an approach that could identify compounds that inhibit RAG cleavage or NHEJ using new chemical libraries.

Indexed as

Drug DiscoveryHigh-Throughput Screening AssaysDNA Breaks, Double-StrandedDNA End-Joining RepairDose-Response Relationship, DrugFlow CytometryHomologous RecombinationHumansMolecular StructurePrecursor Cells, B-LymphoidV(D)J Recombinationcancer and cancer drugscell-based assaysimmune system diseasesoncology

Identifiers

PMID29232168
PMCPMC5997544
OpenAlexW2772068152

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.